Teprotumumab - A Review of Its Adverse Effects Profile.

Published in: The Journal of clinical endocrinology and metabolism (2023)

The use of teprotumumab should consider patient's values and preferences in balancing the expected benefit with these potential risks. Future drugs targeting IGF-1R should investigate these adverse effects for a possible class effect. Combination therapies with different agents hopefully will be identified that maximize benefits and minimize risks.

Keyphrases

human health
risk assessment
case report
current status
climate change
cancer therapy
pi k akt
decision making
binding protein